Gary C. Cupit
MRC Associates, USA
Title: Biosimilars market access and penetration in the obamacare era –considerations for providers, payers, prescribers and patients
Biography
Biography: Gary C. Cupit
Abstract
• Understand the type of FDA approval (abbreviated versus full stop BLA) impacting reimbursement • Understand how labeling will mandate the promotion of biosimilars • Understanding the differing perspectives on physician and patient perceptions of interchangeability • Understanding the challenges of pharmacovigilance and the use of Big Data to monitor safety • Understand how stakeholders at the states level can determine switching or uptake based on interpreting best practices for prescriber and patient communication • Understand lessons from the EU and their impact on the US utilization of biosimilars